A case of recurrent pyoderma gangrenosum injection site reaction triggered by Maveropepimut-S (previously known as DPX-Survivac) in a patient undergoing immunotherapy for ovarian cancer: A case report.

maveropepimut-S (MVP-S) - BioVaxys

http://www.ncbi.nlm.nih.gov/pubmed/41551106

Abdulhadi Jfri; Ali Alajmi; David Nassim; Ivan V Litvinov; Meghan Kanou; Zeinah Alhalees

Jan 19, 2026